Sélectionner une page
Logo Company

Enterosys

Maxime FONTANIÉ

Chief Executive Officer

Who are we?

In 2040, 600 million people will suffer from type 2 diabetes (T2D) and co-morbidities. While current treatments have side effects, ENTEROSYS proposes new therapeutic strategies to treat T2D by targeting the couple “enteric nervous system (ENS) / intestinal contraction” via natural and orally deliverable peptides. Thus, ENTEROSYS develops a portfolio of proprietary peptides to modulate 1) local glucose absorption and 2) the ENS to brain axis to treat hyperglycemia, insulin-resistance and gastrointestinal disorders of T2D patients. Bioactive peptides developed by ENTEROSYS have a very specific site of action (i.e. the duodenum) without side effects in the whole body. Our business model is the development of bioactive molecules up to phase 1 or 2a and licensing-out innovative peptides to R&D industrial partners.